Jerome L. Greene Sjögren's Syndrome Center, Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, USA. Present address: National and Kapodistrian University of Athens, Greece.
Nephrology Division, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):123-132. Epub 2019 Aug 28.
Overt renal disease in primary Sjögren's syndrome (pSS) manifests as interstitial nephritis and glomerulonephritis. This single centre study aims to describe the natural history and treatment outcome of renal disease in pSS.
pSS patients with renal disease were identified, and clinical features, renal biopsy findings, treatment details and renal outcome were recorded.
Of the 20 pSS patients with renal disease, 14 had interstitial nephritis (IN), 3 had glomerulonephritis (GN) and 3 had both entities. In the IN group, 3 patients presented with chronic kidney disease (CKD), 4 with renal tubular acidosis (RTA), 2 with symptomatic hypokalaemia, 4 with renal colic and 1 with haematuria/proteinuria. Eight of 14 patients with IN received systemic immunosuppression (IS) during renal disease course and in 6 patients no beneficial effect was observed on renal function, hypokalaemia and RTA. Six of 14 IN patients developed CKD while 5 of them preserved normal renal function during follow-up. In the GN group, 2 patients presented with CKD, 3 with proteinuria/haematuria and 1 with nephrotic proteinuria. GN renal biopsy findings revealed membranoproliferative (MPGN) (n=3), focal segmental glomerulosclerosis (n=1) and fibrillary glomerulopathy (n=1). All 3 MPGN patients had cryoglobulinaemia and in 1 patient cryoglobulinaemic MPGN was clinically diagnosed. All GN patients were treated with immunosuppressive therapy, with stabilisation or improvement of renal function in the 4 cryoglobulinaemia-associated GN patients only.
Interstitial nephritis follows a slow course and does not improve with systemic immunosuppression while GN has a favourable treatment response in those with MPGN pathology.
原发性干燥综合征(pSS)中的显性肾脏疾病表现为间质性肾炎和肾小球肾炎。本单中心研究旨在描述 pSS 患者肾脏疾病的自然病程和治疗结果。
确定患有肾脏疾病的 pSS 患者,并记录其临床特征、肾脏活检结果、治疗细节和肾脏结局。
在 20 例患有肾脏疾病的 pSS 患者中,14 例患有间质性肾炎(IN),3 例患有肾小球肾炎(GN),3 例同时患有这两种疾病。在 IN 组中,3 例患者出现慢性肾脏病(CKD),4 例出现肾小管酸中毒(RTA),2 例出现症状性低钾血症,4 例出现肾绞痛,1 例出现血尿/蛋白尿。14 例 IN 患者中有 8 例在肾脏疾病过程中接受了全身免疫抑制(IS)治疗,但在 6 例患者中,肾功能、低钾血症和 RTA 均未见有益效果。14 例 IN 患者中有 6 例发展为 CKD,其中 5 例在随访期间肾功能正常。在 GN 组中,2 例患者出现 CKD,3 例患者出现蛋白尿/血尿,1 例患者出现肾病性蛋白尿。GN 肾脏活检结果显示膜增生性肾小球肾炎(MPGN)(n=3)、局灶节段性肾小球硬化(FSGS)(n=1)和纤维状肾小球病(n=1)。3 例 MPGN 患者均伴有冷球蛋白血症,1 例患者临床诊断为冷球蛋白血症性 MPGN。所有 GN 患者均接受免疫抑制治疗,仅在 4 例冷球蛋白血症相关 GN 患者中肾功能稳定或改善。
间质性肾炎呈缓慢进展,全身免疫抑制治疗无效,而 MPGN 病理的肾小球肾炎治疗反应良好。